• Explore /
  • Poster
  • / Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.

Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.

Abstract Poster

Authors

Li Zhang

Li Zhang

Sun Yat-Sen University Cancer Center, Guangzhou, China

Li Zhang , Wenfeng Fang , Yuanyuan Zhao , Yunpeng Yang , Ningning Zhou , Likun Chen , Yan Huang , Jianhua Chen , Li Zhuang , Yingying Du , Wu Zhuang , Qitao Yu , Yanqiu Zhao , Ming Zhou , Weidong Zhang , Yu Zhang , Yixin Wan , Weifeng Song , Yu Xia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04736823

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9087)

DOI

10.1200/JCO.2023.41.16_suppl.9087

Abstract #

9087

Poster Bd #

75

Abstract Disclosures

Similar Posters

First Author: Yuangyuan Zhao

First Author: Wenfeng Fang

First Author: Martin Reck

First Author: Mingfang Xu